Higher thalidomide dose benefits patients with high-risk disease
| No. risk factors* . | Thalidomide dose of more than 42 g/3 mo . | No. patients . | PPR by at least 25% . | P . | % alive at 2 y . | P . |
|---|---|---|---|---|---|---|
| ≤ 1 | yes | 55 | 45 | .01 | 74 | NS |
| no | 36 | 19 | 66 | |||
| ≥ 1 | yes | 28 | 43 | .02 | 42 | .01 |
| no | 30 | 13 | 20 |
| No. risk factors* . | Thalidomide dose of more than 42 g/3 mo . | No. patients . | PPR by at least 25% . | P . | % alive at 2 y . | P . |
|---|---|---|---|---|---|---|
| ≤ 1 | yes | 55 | 45 | .01 | 74 | NS |
| no | 36 | 19 | 66 | |||
| ≥ 1 | yes | 28 | 43 | .02 | 42 | .01 |
| no | 30 | 13 | 20 |
Risk factors are β2-microglobulin > 3 mg/L, plasma cell labeling index > 0.5%, and abnormal cytogenetics.